ePrints

Clinically targeted screening for congenital CMV - potential for integration into the National Hearing Screening Programme

Lookup NU author(s): Dr Eleri Williams, Professor Janet Berrington

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Screening for a condition should only be undertaken if certain strict criteria are met. Congenital CMV (cCMV) is a leading cause of sensorineuronal hearing loss (SNHL) and meets many of these criteria, but is not currently screened for in the UK. Ganciclovir reduces CMV-induced progressive SNHL if treatment is begun in the first month of life. The Newborn Hearing Screening Programme (NHSP) has been shown to identify SNHL at the earliest possible age. The potential of integrating screening for cCMV into the NHSP is discussed to consolidate the link between screening, early diagnosis and management.Conclusion The early diagnosis and treatment of cCMV may prevent a small proportion of late SNHL. In the absence of any screening programme, we provide evidence that clinically targeted screening through the NHSP is a potential option in the UK, enhancing the diagnostic pathway and enabling appropriate early treatment to reduce long-term morbidity.

Publication metadata

Author(s): Kadambari S, Luck S, Davis A, Williams EJ, Berrington J, Griffiths PD, Sharland M

Publication type: Article

Publication status: Published

Journal: Acta Paediatrica

Year: 2013

Volume: 102

Issue: 10

Pages: 928-933

Print publication date: 01/10/2013

Online publication date: 08/08/2013

Acceptance date: 25/06/2013

ISSN (print): 0803-5253

ISSN (electronic): 1651-2227

Publisher: Wiley-Blackwell

URL: http://dx.doi.org/10.1111/apa.12335

DOI: 10.1111/apa.12335

Altmetrics

Share